Literature DB >> 21653535

HIV and chronic obstructive pulmonary disease: is it worse and why?

Alison Morris1, M Patricia George, Kristina Crothers, Laurence Huang, Lorrie Lucht, Cathy Kessinger, Eric C Kleerup.   

Abstract

Smoking-related diseases, such as chronic obstructive pulmonary disease (COPD), are of particular concern in the HIV-infected population. Smoking rates are high in this population, and long-term exposure to cigarette smoke in the setting of HIV infection may increase the number of complications seen. Before the era of combination antiretroviral therapy, HIV-infected persons were noted to have an accelerated form of COPD, with significant emphysematous disease seen in individuals less than 40 years old. Unlike many of the AIDS-defining opportunistic infections, HIV-associated COPD may be more common in the current era of HIV because it is frequently reported in patients without a history of AIDS-related pulmonary complications and because many aging HIV-infected individuals have had a longer exposure to smoking and HIV. In this review, we document the epidemiology of HIV-associated COPD before and after the institution of combination antiretroviral therapy, review data suggesting that COPD is accelerated in those with HIV, and discuss possible mechanisms of HIV-associated COPD, including an increased susceptibility to chronic, latent infections; an aberrant inflammatory response; altered oxidant-antioxidant balance; increased apoptosis associated with HIV; and the effects of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653535      PMCID: PMC3132792          DOI: 10.1513/pats.201006-045WR

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  61 in total

1.  Hypothesis: does COPD have an autoimmune component?

Authors:  A Agustí; W MacNee; K Donaldson; M Cosio
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 2.  The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy.

Authors:  Jessica R Grubb; Anne C Moorman; Rose K Baker; Henry Masur
Journal:  AIDS       Date:  2006-05-12       Impact factor: 4.177

Review 3.  Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease.

Authors:  Leonard H Calabrese; Elizabeth Kirchner; Rabin Shrestha
Journal:  Semin Arthritis Rheum       Date:  2005-12       Impact factor: 5.532

4.  Emphysema-like pulmonary disease associated with human immunodeficiency virus infection.

Authors:  P T Diaz; T L Clanton; E R Pacht
Journal:  Ann Intern Med       Date:  1992-01-15       Impact factor: 25.391

5.  Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.

Authors:  Kristina Koppel; Göran Bratt; Sam Schulman; Håkan Bylund; Eric Sandström
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

6.  Oxidant stress is increased during treatment of human immunodeficiency virus infection.

Authors:  Todd Hulgan; Jason Morrow; Richard T D'Aquila; Stephen Raffanti; Michael Morgan; Peter Rebeiro; David W Haas
Journal:  Clin Infect Dis       Date:  2003-11-19       Impact factor: 9.079

7.  Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1(+) smokers with early emphysema.

Authors:  Robert J Kaner; Francisco Santiago; Ronald G Crystal
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

8.  Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

Authors:  Handan Wand; Alexandra Calmy; Dianne L Carey; Katherine Samaras; Andrew Carr; Matthew G Law; David A Cooper; Sean Emery
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

9.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

10.  Role of cytokines in alveolar macrophage accessory cell function in HIV-infected individuals.

Authors:  H L Twigg; G K Iwamoto; D M Soliman
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

View more
  53 in total

1.  An increased risk for fractures: another cause of frailty in HIV-infected subjects.

Authors:  Carmine Gazzaruso
Journal:  Endocrine       Date:  2012-06       Impact factor: 3.633

2.  Pulmonary Function in HIV-Infected Recreational Drug Users in the Era of Anti-Retroviral Therapy.

Authors:  Joseph A Simonetti; Matthew R Gingo; Lawrence Kingsley; Cathy Kessinger; Lorrie Lucht; Gk Balasubramani; Joseph K Leader; Laurence Huang; Ruth M Greenblatt; John Dermand; Eric C Kleerup; Alison Morris
Journal:  J AIDS Clin Res       Date:  2014-11

3.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

4.  Screening for Chronic Obstructive Pulmonary Disease (COPD) in an Urban HIV Clinic: A Pilot Study.

Authors:  Daniel K Shirley; Robert J Kaner; Marshall J Glesby
Journal:  AIDS Patient Care STDS       Date:  2015-02-27       Impact factor: 5.078

5.  Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening.

Authors:  Keith Sigel; Juan Wisnivesky; Shahida Shahrir; Sheldon T Brown; Amy Justice; Joon Kim; Maria C Rodriguez-Barradas; Kathleen M Akgün; David Rimland; Guy W Soo Hoo; Kristina Crothers
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

Review 6.  Management of chronic obstructive pulmonary disease-A position statement of the South African Thoracic Society: 2019 update.

Authors:  Mohamed Sabeer Abdool-Gaffar; Gregory Calligaro; Michelle Lianne Wong; Clifford Smith; Umesh Gangaram Lalloo; Coenraad Frederik Nicolaas Koegelenberg; Keertan Dheda; Brian William Allwood; Akhter Goolam-Mahomed; Richard Nellis van Zyl-Smit
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

7.  Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study.

Authors:  Alex Kayongo; Adaeze C Wosu; Tasmia Naz; Faith Nassali; Robert Kalyesubula; Bruce Kirenga; Robert A Wise; Trishul Siddharthan; William Checkley
Journal:  COPD       Date:  2020-05-28       Impact factor: 2.409

Review 8.  Pathogenesis of HIV and the lung.

Authors:  Matthew R Gingo; Alison Morris
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 9.  Human immunodeficiency virus-associated obstructive lung diseases.

Authors:  Matthew R Gingo; Alison Morris; Kristina Crothers
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 10.  Evaluation of respiratory disease.

Authors:  Sofya Tokman; Laurence Huang
Journal:  Clin Chest Med       Date:  2013-04-15       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.